Take a deeper dive into RSV


Quality of life burden on United States infants and caregivers due to lower respiratory tract infection and adjusting for selective testing

A pilot prospective observational study estimating the quality of life (QoL) for otherwise healthy term US infants with RSV-LRTI and their caregivers.

Infants admitted to US intensive care units for RSV infection during the 2022 seasonal peak

A surveillance study of 600 infants across 39 hospitals requiring intensive care for RSV infection found that most were delivered full-term and previously healthy.

Optimal site of care for administration of extended half-life respiratory syncytial virus (RSV) antibodies to infants in the United States (US)

A study to assess the time from birth hospitalization discharge to the first outpatient visit among US infants in order to determine optimal site of administration for the extended half-life antibody.


Beyfortus is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in:

  • Neonates and infants born during or entering their first RSV season.
  • Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

Important safety information


Beyfortus is contraindicated in infants and children with a history of serious hypersensitivity reactions, including anaphylaxis, to nirsevimab-alip or to any of the excipients.

Warnings and Precautions

  • Hypersensitivity Including Anaphylaxis: Serious hypersensitivity reactions, including anaphylaxis, have been observed with other human IgG1 monoclonal antibodies. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, initiate appropriate medications and/or supportive therapy.
  • Use in Individuals with Clinically Significant Bleeding Disorders: As with other IM injections, Beyfortus should be given with caution to infants and children with thrombocytopenia, any coagulation disorder or to individuals on anticoagulation therapy.

Most common adverse reactions with Beyfortus were rash (0.9%) and injection site reactions (0.3%).

Click here to learn more about Sanofi’s commitment to fighting counterfeit drugs.